Payment overview · 2025
General Payments
$582.15
11 reported records · 6 companies
Healthcare provider profile · identity verified
Michael S Lumberg, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TROY, MI · NPI 1700853447
Verified facts
What the public records show
CMS Open Payments records show Michael S Lumberg, MD received $582.15 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.95 | 27.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $133.29 | 22.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.26 | 21.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.84 | 20.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.81 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.00 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $582.15 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $125.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.26 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| ALINITY Normalized: alinity |
Device | Abbott Laboratories | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.44 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.44 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 608 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 91 |
| Losartan Potassium | Losartan Potassium | 335 | 88 |
| Lisinopril | Lisinopril | 296 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 68 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 237 | 69 |
| Omeprazole | Omeprazole | 199 | 63 |
| Carvedilol | Carvedilol | 195 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 51 |
| Jardiance | Empagliflozin | 168 | 58 |
| Alprazolam | Alprazolam | 155 | 49 |
| Ezetimibe | Ezetimibe | 146 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 45 |
| Simvastatin | Simvastatin | 143 | 38 |
| Metformin Hcl | Metformin Hcl | 142 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 117 | 31 |
| Meloxicam | Meloxicam | 101 | 38 |
| Tramadol Hcl | Tramadol Hcl | 96 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 19 |
| Bupropion Xl | Bupropion Hcl | 91 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 90 | 24 |
| Ozempic | Semaglutide | 87 | 15 |
| Sertraline Hcl | Sertraline Hcl | 87 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 24 |
| Prednisone | Prednisone | 82 | 54 |
| Eliquis | Apixaban | 80 | 20 |
| Allopurinol | Allopurinol | 79 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 21 |
| Gabapentin | Gabapentin | 71 | 16 |
| Trazodone Hcl | Trazodone Hcl | 68 | 17 |
| Famotidine | Famotidine | 64 | 24 |
| Montelukast Sodium | Montelukast Sodium | 64 | 12 |
| Mounjaro | Tirzepatide | 59 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 15 |
| Metformin Hcl Er | Metformin Hcl | 58 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 14 |
| Furosemide | Furosemide | 51 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 48 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 16 |
| Atenolol | Atenolol | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | suppressed |
| Glimepiride | Glimepiride | 41 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 25 | 25 |
| Potassium Chloride | Potassium Chloride | 25 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 16 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Testosterone | Testosterone | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $582.15 · 11 records | Novo Nordisk Inc | AIRSUPRA, ALINITY, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error